In a primary test of the effects of several FDA-approved central nervous system drugs (including ropinirole, a dopamine agonist that is used to treat Parkinson’s disease; CPZ; and aspirin) on autophagy, we performed a biochemical analysis to examine the level of LC3-II/I, which correlates with the number of autophagosomes, and we unexpectedly found that CPZ treatment strikingly increased the level of LC3-II/I compared with control, ropinirole, or aspirin treatments in HEK 293 cells (Figure 1A). The gene discussed is CPZ; the disease is Parkinson disease.